Molecular signature
Deficient mismatch repair (dMMR)
Deficient mismatch repair (dMMR) is a molecular signature biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (5), each linked to its source.
Matched identity
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA companion diagnostic
An FDA-cleared or approved companion diagnostic names this biomarker.
Source-level evidence only
Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.
FDA companion diagnostic assertions (5)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| MMR IHC Panel pharmDx (Dako Omnis) | Deficient mismatch repair (dMMR) proteins | Agilent Technologies, Inc. | Colorectal Cancer (CRC) | 2025-08-15 |
| Ventana MMR RxDx Panel | Deficient mismatch repair (dMMR) proteins | Ventana Medical Systems, Inc. | Endometrial Carcinoma (EC) | 2024-12-18 |
| Ventana MMR RxDx Panel | deficient mismatch repair (dMMR) proteins | Ventana Medical Systems, Inc. | Solid Tumors | 2022-03-21 |
| Ventana MMR RxDx Panel | Deficient mismatch repair (dMMR) proteins | Ventana Medical Systems, Inc. | Solid Tumors | 2021-08-17 |
| Ventana MMR RxDx Panel | Deficient mismatch repair (dMMR) proteins | Ventana Medical Systems, Inc. | Endometrial Carcinoma (EC) | 2021-04-22 |
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.